[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532757":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Chlamydia trachomatis (CT) and\u002For Neisseria gonorrhoeae (NG) NAAT(s)","Test every week after the start of treatment, until NAAT negativation and up to a maximum of 4 weeks",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Axel Ursenbach, MD","CONTACT","0033.88.15.13.52","axel.ursenbach@chru-strasbourg.fr",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Service du Trait d'Union","RECRUITING","Strasbourg","67000","France","FR",{"type":28,"coordinates":29},"Point",[30,31],7.74553,48.58392,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":7,"phoneExt":7,"email":7},"Axel URSENBACH, MD",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100532757",false,"NCT06216964","Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study","DECHLAGO","Inclusion Criteria:\n\n* \\- Patients attending the Trait d'Union department at the Nouvel Hôpital Civil for PrEP consultations, AES or HIV infection.\n* Over 18 years of age\n* Male or female\n* Who have had an uncomplicated CT and\u002For NG infection treated with currently recommended therapies (Ceftriaxone 500mg DU for NG infections, Doxycycline 200mg per day for 1 week for rectal CT infections and Azithromycin 1g DU or Doxycycline 7 days for other CT infections).\n* Subject affiliated to a social health insurance scheme\n* Subject able to understand the aims and risks of the research and to give dated and signed informed consent\n\nExclusion Criteria:\n\n* \\- Complicated CT and\u002For NG infections: epididymitis, prostatitis, upper genital infection, extra-genital involvement (keratoconjunctivitis, arthritis, skin involvement, Fiessinger-Leroy-reiter syndrome, Fitz-Hugh-Curtis syndrome).\n* Interfering treatments and associated diseases: Severe immunosuppression (HIV infection with CD4 less than 200\u002Fmm3, chemotherapy in the last 6 months, active haemopathy, congenital immune deficiency, immunosuppressive treatment including corticosteroid therapy for more than 4 weeks or organ transplant.\n* Impossibility of giving the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.).\n* Subject under court protection\n* Subject under guardianship or curatorship","ALL","18 Years",{"count":47,"type":48},140,"ESTIMATED","INTERVENTIONAL",[51],"NA","The aim of this study is to evaluate the negativation time of chlamydial and gonococcal PCRs after treatment for urogenital, oropharyngeal and anal infections.",[54,55,56],"Chlamydia Trachomatis","Neisseria Gonorrhoeae","Uncomplicated Infections","2025-08-01",{"date":59,"type":60},"2025-08-03","ACTUAL",{"date":62,"type":60},"2024-04-05",{"date":64,"type":48},"2027-11-01",{"name":5,"class":6},1]